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ARE OLIGONUCLEOTIDE PRIMERS AND PROBES
PRIMA FACIE OBVIOUS OVER LARGER PRIOR ART
NUCLEIC ACIDS?
Jeffery Fredmant
I. INTRODUCTION
While the Court of Appeals for the Federal Circuit [hereinafter
CAFC] has decided that large nucleic acid sequences are nonobvious
when the prior art teaches only shorter sequences, the converse
question remains unaddressed, i.e. whether small nucleic acid
sequences are obvious in view of the larger nucleic acid sequences
that comprise them? This Comment approaches the question of
"prima facie obviousness" in these smaller sequences through two
hypothetical patent claims that are drawn to nucleic acid
oligonucleotides. This Comment will analyze seven common prior
art situations, as applied to the two hypothetical patent claims, to
determine whether for each prior art situation the hypothetical claims
are prima facie obvious in light of the relevant case law.
II. BACKGROUND
As the pace of advancement in biotechnology increases
exponentially and the databases which store nucleic acid sequences
double every year,1 increasingly complex issues of intellectual
property leave the laboratory and enter the courtroom. Nucleic acid
sequences serve as a resource for the bioinformatics researcher and
molecular biologist alike to design new tests and assays.2 Some tests
have been designed to diagnose diseased patients and identify the
specific organism suspected of causing the symptoms, thereby leading
to a specific treatment.3 Another test has been designed to identify
genetic mutations in a pig that cause enhanced litter size. The test
t Jeffery Fredman is currently a Primary Examiner for the USPTO, and J.D. candidate
at The George Washington University Law School. He holds a Ph.D. in Biochemistry from the
University of Alabama at Birmingham. The opinions expressed in this Comment are solely
those of the author, but are derived from his experiences as a scientist and a patent examiner.
1. David S. Roos, Bioinformatics-Trying to Swim in a Sea of Data, 291 SCi. 1260
(2001).
2. See Sylvia J. Spengler, Bioinformatics in the Information Age, 287 SCI. 1221 (2000).
3. See U.S. Patent No. 6,214,583 (issued April 10, 2001).
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allows farmers to select pigs with increased fecundity, which can in
turn lead to reduced farm costs. 4 These tests rely on the use of small
pieces of deoxyribonucleic acid (DNA), oligonucleotides, which are
termed either "primers" or "probes," depending upon their use.5
Probes and primers are pieces of DNA which contain specific
information encoded by the four nucleotide base codes, A, C, G, T
(Adenine, Guanine, Cytosine, or Thymidine).6 Probes interact with
other pieces of DNA in a hybridization reaction, wherein a specific
probe with a specific sequence of nucleotides will interact with a
complementary sequence in a target nucleic acid.7 Primers are a
subset of probes with the further capacity to be extended in length by
addition of nucleotides in a sequence-specific manner in a catalytic
process employing a DNA polymerase enzyme.8
This Comment will address the question of whether and when
oligonucleotide probes and primers are obvious under a variety of
prior art situations. Figure 1 discloses the seven different nucleotide
prior art situations that will be used. These sample claims will be
analyzed under current case law to yield conclusions regarding the
prima facie obviousness of the exemplary claims. Embedded in the
CAFC case law are three approaches that are used to address the
obviousness of DNA-based claims. These approaches are based upon
(i) chemical case law, decisions that existed prior to the
biotechnology revolution which interpret oligonucleotide claims from
a chemical composition perspective; (ii) genus-species type case law,
which approaches the obviousness of oligonucleotide claims as
individual species in relation to the genus from which they derive;
and (iii) some recent biotechnology-specific case law that is focused
on issues regarding the obviousness and possession of
biotechnological inventions. These three approaches will be
individually applied in analyzing the level of obviousness in the
exemplary claims.
III. OBVIOUSNESS ANALYSIS
A. Basic Principles
The statutory language in the Patent Act that addresses
4. See U.S. Patent No. 5,939,264 (issued August 17, 1999).
5. See BENJAMIN LEWIN, GENES V 633-656 (Oxford University Press 1994).
6. See id. at 633.
7. See id. at 644.
8. See Optimization of PCRs, PCR PROTOCOLS A GUIDE TO METHODS AND
APPLICATIONS 9-10 (Michael A. Innis et al. eds., Harcourt Brace Jovanovich 1990).
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obviousness provides the starting point in analyzing the nature of each
of the seven situations provided in Figure 1. The applicable section is
35 U.S.C. § 103(a), which states in significant part,
[a] patent may not be obtained though the invention is not
identically disclosed or described as set forth in section 102 of this
title, if the differences between the subject matter sought to be
patented and the prior art are such that the subject matter as a
whole would have been obvious at the time the invention was
made to a person having ordinary skill in the art to which said
subject matter pertains. Patentability shall not be negatived by the
manner in which the invention was made.
9
The Supreme Court analyzed the statute in Graham v. John
Deere Co. and developed the following analysis for determining
whether a claim was nonobvious over the relevant prior art:
Under § 103, the scope and content of the prior art are to be
determined; differences between the prior art and the claims at
issue are to be ascertained; and the level of ordinary skill in the
pertinent art resolved. Against this background, the obviousness or
nonobviousness of the subject matter is determined.' 0
It is the relationship of the Graham analytical factors that guides
the prima facie obviousness determination. Obviousness is
determined by focusing on whether the individual of ordinary skill in
the art, when analyzing the relevant prior art, would have found the
differences between that prior art and the patent claims at issue to be
obvious.' Each of the three factors, along with any evidence of
secondary considerations, must be weighed as a whole to make the
prima facie obviousness determination. 12 The first inquiry identified
by the Supreme Court involves characterizing the prior art. 3
B. Prior Art
The first of the Graham factors addresses the scope and content
of the prior art. In the oligonucleotide context, a significant body of
prior art exists which discusses the parameters and objectives
9. 35 U.S.C. § 103(a) (2000).
10. Graham v. John Deere Co., 383 U.S. 1, 17 (1966). Certiorari was granted in two
related patent infringement appeals from the Eighth Circuit Court of Appeals, 333 F.2d 529, and
336 F.2d 110. The Court, held that the provisions in the Patent Act pertaining to
nonpatentability due to obviousness were intended to codify judicial precedent, and that the
general level of innovation necessary to sustain patentability remains the same. The patents at
issue were invalid due to obviousness of subject matter. Id.
11. Seeid. at l9.
12. Id.
13. Id.
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involved in the selection of oligonucleotides that function as probes
and primers.14 A specific example is the Hogan et al. teaching probe
selection, which provides for specific identifications in bacterial
ribosomal RNAs. It states,
Once the variable regions are identified, the sequences are aligned
to reveal areas of maximum homology or 'match'. At this point,
the sequences are examined to identify potential probe regions.
Two important objectives in designing a probe are to maximize
homology to the target sequence(s) (greater than 90% homology is
recommended) and to minimize homology to non-target
sequence(s) (less than 90% homology to non-targets is
recommended). 15
There are, in fact, many Internet Web sites that provide free
downloadable software to aid in the selection of primers drawn from
genetic data recorded in a spreadsheet. 16 Other sites will freely permit
primer selection using Web based applications. 17 Thus, the prior art is
replete with guidance and information necessary to permit the
ordinary artisan in the field of nucleic acid detection to design primers
and probes.
Figure 1 illustrates seven hypothetical oligonucleotides
compared against relevant prior art sequences. In each of the
examples given, there are two parameters which vary: the sequence
itself, and the length of the sequence. It is the interaction of these two
parameters, in conjunction with the prior art and the proper legal
analysis, that determines the obviousness of any particular nucleic
acid sequence. The first hypothetical situation shown is where the
oligonucleotide has no homology with any known prior art sequence
whatsoever, as exemplified in Panel A. The second situation is where
the oligonucleotide is perfectly complementary to a prior art
oligonucleotide of identical length and sequence, as shown in Panel
B. The vertical lines between the bases represent a convention that
the nucleotide bases in the code are identical. Where there are no
vertical lines, the nucleotide bases are divergent or have a
14. See, e.g., K. Agarwal et al., A General Method for Detection and Characterization of
an mRNA Using an Oglionucleotide Probe, 256 J. BIOLOGICAL CHEMISTRY 1023 (1981); A.
Sharrocks, The Design of Primers for PCR, PCR TECH.: CURRENT INNOVATIONS 5-11 (H.G.
Griffin & A.M. Griffin eds., 1994).
15. WO 87/03009,12-13 (1987).
16. Steven Strain & Jerry G. Chmielewski, ROCK: A Spreadsheet-Based Program of the
Generation and Analysis of Random Oligonucleotide Primers Used in PCR, at
http://www.sru.edu/depts/artsci/bio/rock.htm (last revised June 13, 2001).
17. Medical Research Council, Welcome to the Genome Web Primer Design, at
http://www.hgmp.mrc.ac.uk/GenomeWeb/nuc-primer.html (last visited November 24, 2002).
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mismatched nucleotide base. The third situation is where the entire
sequence from which the oligonucleotide is derived is known in the
prior art, as shown in Panel C. The fourth situation is where, not only
is the entire sequence from which the oligonucleotide derived known
in the prior art, but there is another oligonucleotide from the same
sequence in the prior art as well, as shown in Panel D. The fifth
situation is where, not only is the entire sequence from which the
oligonucleotide derived known in the prior art, but there is an
overlapping oligonucleotide in the prior art as well, as shown in Panel
E. The sixth situation is where the prior art sequence from which the
oligonucleotide is derived has a mismatch or different nucleotide with
the oligonucleotide, as shown in Panel F. The seventh situation is
where the oligonucleotide is longer than the prior art sequence, as
shown in Panel G. These seven hypothetical situations, which
epitomize the most common prior art that is available in
oligonucleotide cases, represent the prior art which will be further
analyzed in this Comment.
C. Claims Analysis-Anticipation and Nonobviousness
The second Graham factor involves analyzing the differences
between the prior art and the claims at issue. Two separate claims are
considered in the obviousness inquiry for the sample sequences in the
figure. The only difference between the claims is the "transitional"
phrase. Claim I uses the open language phrase "comprising" whereas
Claim 2 uses the closed language phrase "consisting of."18  The
hypothetical claims state:
Claim 1, an isolated oligonucleotide comprising
GCAGAGTACTATCGATG, and Claim 2, an isolated
oligonucleotide consisting of GGCAGAGTACTATCGATG. The
sequence disclosed in the claims is the sequence represented by the
oligonucleotide in Figure 1.
In analyzing the seven situations in the figure against Claims 1
and 2, two of the situations are immediately resolved for either claim.
Since there is no prior art in Panel A, there can be no analysis of the
differences, thus the claims are considered "nonobvious." The
obviousness analysis begins with an inquiry into the scope and
content of the prior art. 19 If this first inquiry reveals no prior art
which can be applied to the claims-because the differences between
any prior art and the claims are too significant for any of the prior art
to be applicable-then the claims are necessarily "nonobvious."
18. See MANUAL OF PATENT EXAMINING PROCEDURE § 2111.03 (8"' ed. 2001).
19. Graham v. John Deere Co., 383 U.S. 1, 17 (1966).
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Panel C
oligonucleotide
AM prior a
Panel D
oligonucleotide
TAMAcIUU3TQ\GMA prior art-oligonucleotide
prior art
Panel E
MMML . c oligonucleotideIIIIIIIIIIIIIIllll
I m p rior art-oligonucleotide
Am prior art
Panel F
G30k3Vnrcnk~ccA oligonucleotide
A prior art
Panel G
GXAGK, 7 oligonucleotide
IrIIi rGAArprior ar
Figure 1. Seven Common Prior Art Examples
Panel A
Goa%7GlacTc~mTG oligonucleotide
Gprior art
Panel B
G aN&ArmcuTG oligonucleotide
I fill fill II pior art
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Panel B shows a situation where a single prior art reference
meets the exact limitations of the claimed invention, thus the claims
are considered "anticipated." 2 ° In this instance, the nonobviousness
inquiry is short-circuited since the claims lack "novelty" under 35
U.S.C. § 102. When a claim is "anticipated," no question of
obviousness is present since the obviousness inquiry only begins if
the claim itself is novel over the prior art. A mere modification of the
prior art may render a claim obvious.
21
Further, analyzing Panels C-E with regard to Claim 1 can be
simplified. In each case the reasonable interpretation of the open term
"comprising" permits the presence of the additional sequence attached
to the ends of the specific oligonucleotide.2 2 Therefore, in Panels C-
E, there are also no differences between the prior art and the
oligonucleotide, rendering Claim 1 anticipated by the prior art. Claim
2, however, is not anticipated by the prior art in Panels C-E, since
there are differences between the prior art and the claim. These
panels will be analyzed later under the relevant case law.
The third Graham element, the level of ordinary skill in the
art, is addressed by
[f]actors that may be considered in determining level of ordinary
skill in the art include (1) the educational level of the inventor; (2)
type of problems encountered in the art; (3) prior art solutions to
those problems; (4) rapidity with which innovations are made; (5)
sophistication of the technology; and (6) educational level of active
workers in the field.
23
It is assumed for the purposes of this Comment that the
educational level of the inventor and active worker in the DNA
diagnostics field is a Ph.D. with several years of postdoctoral
experience. The problems and prior art solutions are also at the
highest level of sophistication with innovation itself proceeding at a
very rapid rate. The level of ordinary skill in this art is therefore
extremely high, and the third Graham element will ordinarily favor a
finding of obviousness. In analyzing the prima facie obviousness of
the prior art situations of Panels F and G as applied to Claim 1, and
Panels C-G as applied to Claim 2, the case law has approached the
prima facie obviousness inquiry in several ways: some
oligonucleotide cases analogize oligonucleotides to chemical
analogues and apply chemical case law; a second approach is to apply
20. MARTIN J. ADELMAN ET AL. CASES AND MATERIALS ON PATENT LAW 389 (1998).
21. See MANUAL OF PATENT EXAMINING PROCEDURE § 706.02 (8 h ed. 2001).
22. See MANUAL OF PATENT EXAMINING PROCEDURE § 2111.01 (8"h ed. 2001).
23. Environmental Designs, Ltd. v. Union Oil Co., 713 F.2d 693, 696 (Fed. Cir. 1983),
cert. denied, 464 U.S. 1043 (1984).
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genus-species case law, which states that small nucleic acid pieces are
"species" of a larger "genus" suggested by the full length sequence;
third, the reasoning in recent biotechnological case law regarding
anticipation and written description of nucleic acids has occasionally
been applied to oligonucleotides.
V. CHEMICAL CASE LAW
In early chemical cases, chemical entities were prima facie
obvious if the claimed compound was "structurally" obvious over a
prior art reference. 24  The Court of Customs and Patent Appeals
[hereinafter CCPA] began from the premise that "in order to be
patentable, novel members of a homologous series of chemical
compounds must possess some unobvious or unexpected beneficial
properties not possessed by a homologous compound disclosed in the
prior art. 25 Chemical entities which were homologous to prior art
entities were prima facie obvious until the applicant rebutted this
obviousness with an evidentiary showing.2 6 The CCPA addressed the
showing necessary to rebut the prima facie case of obviousness in In
re Papesch, where the CCPA found that an applicant who showed
that a novel compound possessed anti-inflammatory properties, which
were not present in a homologous prior art compound, had rebutted
the case of prima facie obviousness. 27 Regarding the assumption that
homologues 2' are identical in properties, the CCPA noted that "[a]n
assumed similarity based on a comparison of formulae must give way
to evidence that the assumption is erroneous. 29 When the CAFC
took up this issue en banc in In re Dillon, the court stated,
This court, in reconsidering this case in banc [sic], reaffirms that
structural similarity between claimed and prior art subject matter,
proved by combining references or otherwise, where the prior art
gives reason or motivation to make the claimed compositions,
creates a primafacie case of obviousness, and that the burden (and
opportunity) then falls on an applicant to rebut that prima facie
24. See Philippe Ducor, Recombinant Products and Nonobviousness: A Typology, 13
SANTA CLARA COMPUTER & HIGH TECH. L.J. 1, 19 (1997).
25. In re Hass, 141 F.2d 122, 128 (C.C.P.A. 1944).
26. See In re Henze, 181 F.2d 196 (C.C.P.A. 1950).
27. See In re Papesch, 315 F.2d 381, 391 (C.C.P.A. 1963).
28. A chemical homolog is defined as "[b]elonging to or being a series of organic
compounds, each successive member of which differs from the preceding member by a constant
increment." WEBSTER'S I1 NEW RIVERSIDE UNIVERSITY DICTIONARY 589 (Houghton Mifflin
Co. 1984).
29. In re Papesch, 315 F.2d at 391.
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case.
3 0
The CAFC found in Dillon that the triorthoesters and the
tetraorthoesters were equivalent, and that the addition of the single
carbon did not alter the properties of the chemical. 3' The CAFC
clarified that a prima facie case for obviousness of chemical
compounds requires only teachings of the composition by
combination of prior art references with concomitant motivation
present to combine the prior art references. No requirement exists,
however, for the prior art to suggest the same utility as that of the
inventor.
32
This contrasts with the statement of the CAFC in In re
Grabiak that "[u]pon review of this history, we have concluded that
generalization should be avoided insofar as specific chemical
structures are alleged to be prima facie obvious one from the other."
33
In that statement, and in later cases, such as In re Jones, specific
motivation to make the change in the chemical structure seems to be
required.34 The CAFC appears to be moving from a requirement of
"motivation to make the compound" to a requirement of "motivation
to make the specific change which results in the new compound." In
part, this may be due to a belief that the unpredictability of the
chemical arts should be reflected in the prima facie obviousness
analysis.35
One application of the chemical case law to a
biotechnological invention is found in In re Mayne, where the CAFC
analyzed the obviousness of a modified protein. The relevant prior art
consisted of a primary reference which taught the making of fusion
proteins, a secondary reference which taught the specific cleavage
sites in fusion proteins, and another secondary reference which taught
a number of chemical cleavage sites which shared some structural
similarity with the claimed compound.36 Once the CAFC found that
there were structural similarities sufficient to form a prima facie case,
the CAFC reviewed the evidence of secondary considerations.37 The
CAFC found that the evidence presented failed to support a
determination of unexpected results.38 As a result, this case would
30. In re Dillon, 919 F.2d 688, 692 (Fed. Cir. 1990) (emphasis added).
31. See id. at 693.
32. Id.
33. In re Grabiak, 769 F.2d 729, 733 (Fed. Cir. 1985) (emphasis added).
34. See In re Jones, 958 F.2d 347, 351 (Fed. Cir. 1992).
35. See William Marsillo, How Chemical Nomenclature Confused the Courts, 6 U. BALT.
INTELL. PROP. L.J. 29, 30 (1997).
36. See In re Mayne, 104 F.3d 1339, 1343 (Fed. Cir. 1997).
37. See id. at 1343-44.
38. See id. at 1344.
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support a rule that modifications to nucleic acids or proteins, where
the general modification is suggested by a prior art reference, are
prima facie obvious in the absence of secondary considerations.
A. Chemical Case Law Applied to Claim 1
As noted previously, the two significant parameters in
evaluating oligonucleotide claims are the oligonucleotide sequence
and the oligonucleotide length. In Panel F, the two sequences are
essentially identical, with the exception of a single mismatch between
the oligonucleotide and the prior art sequence. It is this similarity
which makes the oligonucleotide a homologue of the prior art
sequence. The chemical case law will be applied next to determine
whether the level of homology renders the claimed oligonucleotide
prima facie obvious.
The homology in the sequence is based upon the fact that
each of the nucleic acid bases are arguably homologous to each other.
As shown in Figure 2, the Thymine and Cytosine bases only differ in
39the placement of a methyl group.
Nucleic Acid Bases
0 H'N H
H H CH 3
N N N
0-;-- N 0 N 0- NI . I .IH H H
urecil thymine cytosine
H '--., N --H N
N N HN N
HH H
adenine guanine
Figure 2. Nucleic Acid Bases
39. A methyl group is a carbon atom linked to three hydrogen atoms. GEOFFREY ZUBAY,
BIOCHEMISTRY 45 (Prentice Hall 1983); see also John Brabson & Adrienne Enfield, Nucleic
Acid Structure, at http://mills.edu/RESEARCH/FUTURES/JOHNB/structurefunction/707.html
(last modified November 14, 1997).
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To argue that the bases are homologous, the proponent would
note that Thymine and Cytosine are both present in essentially all
DNA sequences and that they belong to a class of organic compounds
which differ from one another in fixed locations by one substitution
of an amine 40 for a carbonyl group4 1 and one methyl group.
42
Replacing a Thymine base for a Cytosine base, in an 18 nucleotide
oligonucleotide, composed of hundreds of atoms, would affect the
hybridization properties of the oligonucleotide.43 This mismatch
would cause a ten degree reduction in Tm, 44 as analyzed by the
oligonucleotide properties calculator.45  This means that the
mismatched oligonucleotide would hybridize with a reasonable
degree of specificity. 46  Given the express statement by the Dillon
court that structural similarity is sufficient to provide a prima facie
case of obviousness, the court might support a finding of obviousness
of the oligonucleotide in Panel F in view of the prior art shown.47
The decision in Ex parte Anderson might also support a
finding of prima facie obviousness. In that case, the Board of Patent
Appeals and Interferences affirmed a rejection of a nucleic acid
sequence that differed from another nucleic acid sequence due to an
allelic variation, which resulted in one different amino acid in the
resultant protein.48 Such a molecular modification may be sufficient
for establishing obviousness. 49 The oligonucleotide in Panel F would
be prima facie obvious in light of the structural similarities it shares
with the prior art, despite the mismatched base, because the base is
"chemically" homologous.
The case depicted in Panel F is not as good as the case in In
re Mayne, however, where there was essentially an express
suggestion in the prior art of the particular amino acid that should
40. An amine group is a nitrogen atom linked to two hydrogen atoms. See
BIOCHEMISTRY supra note 39, at 326.
41. A carbonyl group is a carbon atom linked by a double bond to an oxygen atom. Id. at
37.
42. See Brabson & Enfield, supra note 39.
43. See Ulrich Melcher, Molecular Genetics (last updated May 28, 2001), at
http://opbs.okstate.edu/-melcher/MG/MGW1/MG 11120.html.
44. Tm is the melting temperature or the temperature at which 50% of a given
oligonucleotide is hybridized to its complementary strand. See GENES V, supra note 5, at 112-
14.
45. BASIC SCIENCES AT NORTHWESTERN UNIVERSITY MEDICAL SCHOOL (2002),
available at http://www.basic.nwu.edu/biotools/oligocalc.html.
46. Id.
47. See In re Dillon, 919 F.2d 688, 693 (Fed. Cir. 1990).
48. See ExparteAnderson, 30 U.S.P.Q.2d 1866 (BPAI 1994).
49. See Ducor, supra note 24, at 48.
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replace its homologous amino acid.50 In the example, no specific
teaching is present to suggest which, if any, homologous nucleotides
should be altered in the prior art nucleic acid which would result in
formation of the claimed oligonucleotide. If it were directly applied
to the example, Mayne would likely result in a finding that Claim 1 is
nonobvious.
The CAFC made the strong statement in In re Jones that
[c]onspicuously missing from this record is any evidence, other
than the PTO's speculation (if it be called evidence) that one of
ordinary skill in the herbicidal art would have been motivated to
make the modifications of the prior art salts necessary to arrive at
the claimed 2-(2'-aminoethoxy) ethanol salt.
5 1
Following Jones, a change of one homologue for another, in
the absence of particular motivation for the particular change, would
lead to a conclusion of nonobviousness. This motivational problem is
central in Panel F, because there is no reason to alter the particular
nucleotide at that particular position in the oligonucleotide to create
the altered oligonucleotide. As the case law has progressed, the
motivation question appears to have become the central issue. Even
in Dillon, the CAFC seemed to imply a requirement for "motivation
to make the change." In the instant example, no motivation exists
other than a generic observation that alteration of a single nucleotide
in the oligonucleotide would modestly alter the properties if present.
52
Therefore, applying the analysis of Jones to Claim 1, using the prior
art situation of Panel F would very likely result in a finding that the
claim is nonobvious over the prior art.
Applying the reasoning of Dillon and Jones to Panel G, there
are substantial differences between the oligonucleotide and the prior
art. As the prior art sequence is shorter than the oligonucleotide, there
is no teaching of the full length of the oligonucleotide in the prior art.
Further, there is no suggestion or motivation to fill in the missing
nucleotides into the prior art of Panel G, thus the oligonucleotide
would likely be found nonobvious over the prior art of Panel G. 53 It
would appear then that deficiencies in the prior art teachings
regarding the sequence and length of the oligonucleotide mitigate
against a finding of prima facie obviousness for the sequence shown
in Panels G.
50. See In re Mayne, 104 F.3d 1339, 1343 (Fed. Cir. 1997).
51. In re Jones, 958 F.2d 347, 351 (Fed. Cir. 1992) (emphasis added).
52. See Dillon, 919 F.2d at 693.
53. See Jones, 958 F.2d at 351.
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B. Chemical Case law Applied to Claim 2
In regards to Claim 2-where the oligonucleotide is claimed
using the closed language phrase "consisting of'--the anticipation
and nonobvious determinations made regarding Panels A and B
remain the same as the determination for Claim 1. This is because the
prior art deficiency still renders Claim 2 nonobvious in view of Panel
A, while Claim 2 is anticipated in view of the prior art of Panel B.
The analysis of Panels F and G, while tending toward
nonobviousness, remain substantially the same as above, since the
central issue in each of those panels is the absence of teaching an
alteration of a particular nucleotide or nucleotides in the prior art.
The motivation to select a particular oligonucleotide from the larger
sequence is that ordinarily a practitioner will first review the prior art
to identify desirable locations for oligonucleotides.
54
Panels C, D, and E represent increasing levels of structural
similarity between the prior art and the claimed oligonucleotide. In
Panel C, the full length sequence has a region of complete identity,
where every nucleotide perfectly matches between the prior art
oligonucleotide and the hypothetical oligonucleotide of Claim 2, and
the prior art differs only in the length of the sequence. In Panel D, the
prior art not only has the region of complete identity with the
oligonucleotide, but there the prior art teaches of a functionally
homologous oligonucleotide as well .5 In Panel E, the prior art has
the region of complete identity, and the functionally homologous
oligonucleotide in the prior art substantially overlaps the claimed
oligonucleotide, to share a substantial region of complete identity.
In analyzing Panels C, D, and E, besides the prior art
sequence shown in Figure 1, two other types of prior art must be
considered. To begin with, prior art abounds on modes of selection of
primers and probes from larger sequences. This prior art in part,
provides the ordinary practitioner with the ability to select smaller
sequences from larger, known prior art sequences. Abundant prior art
also exists that provides motivation to select primers from larger
sequences, such as that in the Mullis patent.
56
Applying this prior art tableau and the chemical case law to
Panel C, the only difference between the prior art and the
oligonucleotide is the extended length of the prior art relative to the
54. See WO 87/03009, 12-13 (1987).
55. A functionally homologous oligonucleotide is an oligonucleotide that differs in
structure from the reference oligonucleotide, but is capable of performing the same function as
the reference oligonucleotide. For example, two oligonucleotides which can both detect the
same region in a gene of a disease causing organism would be functionally homologous. See
NEW RIVERSIDE DICTIONARY, supra note 28, at 589.
56. See U.S. Patent No. 4,683,202 (issued July 28, 1987).
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oligonucleotide. As noted above, there is prior art which would direct
the selection of primers from larger sequences and there is prior art
which would motivate such a selection, for example, in order to
amplify the sequence of interest.5 7 Applying the chemical case law,
In re Dillon in particular, a prima facie case of obviousness seems to
emerge. In Dillon, the CAFC found that the triorthoesters and the
tetraorthoesters were equivalent, and that the addition of the single
carbon did not alter the properties of the chemical. The situation in
Panel C presents the converse; 58 there is a deletion of nucleotides
from the prior art polynucleotide which is necessary to render the
oligonucleotide obvious.
An ordinary practitioner in biotechnology is aware that any
version of the prior art polynucleotide which comprises the claimed
oligonucleotide would function to hybridize to the same target
molecule. 59 The issue, therefore, is whether there is motivation to
shorten the particular oligonucleotide claimed to the specific sequence
given. Generic motivation to shorten the polynucleotide may be
provided by the earlier references, such as Mullis, which desire
shorter nucleic acids in order to perform the polymerase chain
reaction. 60  The bent of the chemical case law suggests that a
functional and structural homologue is sufficient for a prima facie
case of obviousness. Therefore, case law appears to support the
obviousness of the oligonucleotide in Panel C, based on the prior art
polynucleotide and earlier prior art references.
6
'
Panels D and E represent situations in which the motivation
to make the oligonucleotide is enhanced. In Panel D, for example, a
homologous prior art oligonucleotide provides express motivation for
the detection of the prior art sequence by hybridization or
amplification analysis.62 While the analysis of this Panel is similar to
Panel C, the presence of the homologous oligonucleotide in Panel D
demonstrates that the ordinary practitioner tends to design
oligonucleotides of reduced length, relative to the full length prior art
sequence, and provide a functional homologue to the claimed
57. See Sharrocks, supra note 14.
58. See In re Dillon, 919 F.2d 688, 693 (Fed. Cir. 1990).
59. Natalie Milner et al., Selecting Effective Antisense Reagents on Combinatorial
Oligonucleotide Arrays, 15 NATURE BIOTECHNOLOGY 537 (1997).
60. U.S. Patent No. 4,683,202 (issued July 28, 1987).
61. See Dillon, 919 F.2d at 693.
62. Hybridization is the process of annealing two nucleic acid strands to form the
Watson-Crick duplex structure. Nucleic acid amplification refers to methodologies by which
the amount of certain nucleic acids are increased in a sample by biotechnological processes. See
GENES V, supra note 5, at 1244.
OLIGONUCLEOTIDE PRIMERS AND PROBES 299
oligonucleotide. The case for obviousness in Panel D is stronger than
in Panel C, due to the presence of the prior art homologous
oligonucleotide. Panel E represents a scenario where the prior art is
nearly identical and the oligonucleotide is arguably obvious, but not
anticipated. The prior art teaches not only the full length
polynucleotide from which the oligonucleotide is derived, but also
teaches an overlapping oligonucleotide. The presence of the
overlapping oligonucleotide arguably directs the ordinary practitioner
to a particular part of the prior art polynucleotide, therefore reducing
the amount of variability in the sequence that must be motivated by
the prior art polynucleotide. This represents the strongest case of
prima facie obviousness under the chemical case law because there is
"functional" homology and "structural" similarity with identical
utility in the prior art, as compared to the claimed oligonucleotide.
This case is closest to the situation in Mayne, where there was
express suggestion of the possible alternative enterokinase cleavage
sites, 63 and the CAFC found selection of one site relative to another
enterokinase cleavage site prima facie obvious.64 Therefore, as the
prior art increases in motivation in Panels C-E, it is increasingly
likely that a court would find the claimed oligonucleotide prima facie
obvious over the increasingly close prior art.
VI. GENUS-SPECIES CASE LAW
A different approach to the question of obviousness, as
applied to Claims 1 and 2 and in light of the prior art, is to view the
question as the selection of a species from a larger genus. The
original position of the CCPA on genus-species issues is expressed in
In re Susi. In this case, the CCPA wrote "[a]ppellant is essentially in
the position of one who argues that the selection of a relatively small
subgenus from a genus disclosed in the prior art would have been
unobvious at the time of his invention to one skilled in the art.",65 The
CCPA determined that selection of a species from a genus, absent a
showing of unexpected results, was prima facie obvious.66
The CAFC applied the same reasoning in Merck & Co. v.
Biocraft Laboratories, Inc., where selection of a particular compound
out of 1200 possible prior art compounds in the prior art genus was
63. Site through which the upper intestinal mucosa enzyme enterokinase converts
inactive trypsogen into the digestive enzyme trypsin. AM. HERITAGE DICTIONARY. 745 (3d ed.
1996).
64. See In re Mayne, 104 F.3d 1339, 1342 (Fed. Cir. 1997).
65. In re Susi, 440 F.2d 442, 445 (C.C.P.A. 1970).
66. See id. at 445.
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determined to be obvious.6 7 The obviousness in that case was based
both on the structural similarity of the different compounds and upon
the CAFC's understanding that each and every compound in the
genus would have been expected to function. 68 The CAFC noted that
"any of the 1200 disclosed combinations will produce a diuretic
formulation with desirable sodium and potassium eliminating
,,69properties.
The CAFC cited In re O'Farrell for the proposition that such
a selection of particular species from a prior art genus was not
"obvious to try," but rather that there was a reasonable expectation of
success. 70  Two types of error are identified as "obvious to try" in
0 'Farrell, the first being that,
[i]n some cases, what would have been "obvious to try" would
have been to vary all parameters or try each of numerous possible
choices until one possibly arrived at a successful result, where the
prior art gave either no indication of which parameters were
critical or no direction as to which of many possible choices is
likely to be successful.71
The second type of error is "to explore a new technology or
general approach that seemed to be a promising field of
experimentation, where the prior art gave only general guidance."
72
The CAFC noted that neither type of error applied in Merck, where
the prior art reference "instructs the artisan that any of the 1200
disclosed combinations will produce a diuretic formulation with
desirable sodium and potassium eliminating properties."7 3  That is,
where every member of the genus would be expected to achieve
success, there is a reasonable expectation of success.
The CAFC, when given cases where the genus was
substantially larger, has stepped away from the bright line rule of Susi
that species are prima facie obvious where the genus was in the prior
art. 74 The genus in In re Baird was estimated to encompass more than
100 million different compounds and selection of a single compound
from this genus was required for the rejection.7 5 The CAFC found
67. See Merck & Co. v. Biocraft Laboratories, Inc., 874 F.2d 804, 807 (Fed. Cir. 1989).
68. See id. at 807.
69. Id.
70. Id.
71. In re O'Farrell, 853 F.2d 894, 903 (Fed. Cir. 1988).
72. Id. at 903.
73. Merck & Co. v. Biocraft Laboratories, Inc., 874 F.2d 804, 807 (Fed. Cir. 1989).
74. See Julie A. Hokans, In Re Baird. A New Approach to Obviousness of Chemical
Compounds Introduction, 29 U.C. DAVIS L. REV. 197, 215 (1995).
75. See In re Baird, 16 F.3d 380, 382 (Fed. Cir. 1994).
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that given the large size of the genus, the reference did not render the
claimed invention obvious.76 The CAFC extended this reasoning into
the biotechnology domain in In re Bell, where the court noted,
Bell has argued without contradiction that the Rinderknecht amino
acid sequences could be coded for by more than 1036 different
nucleotide sequences, only a few of which are the human
sequences that Bell now claims. Therefore, given the nearly
infinite number of possibilities suggested by the prior art, and the
failure of the cited prior art to suggest which of those possibilities
is the human sequence, the claimed sequences would not have
been obvious.
77
While the court may wish to avoid a bright line test, it is fairly clear
that, as the number of species in a genus increases, two distinct
thresholds are crossed: anticipation and obviousness.
Professor Adelman, a scholar at the George Washington
University School of Law, identifies six tests which courts have used
to analyze whether a species claim is anticipated by a genus
disclosure. 78 The tests include,
(1) The number of compounds embraced by the most specific prior
art description; (2) The degree of structural similarity between the
compounds of that group; (3) The number of properties shared by
compounds of that group; (4) Whether the properties of the
claimed compounds are the same as, consistent with or
diametrically opposite to the properties disclosed in the prior art;
(5) The number of parameters that can be varied among the most
specifically described group of prior art compounds; and (6)
Whether the claimed materials are physical mixtures or the product
of chemical reactions.
79
These same factors can serve as a guide for the obviousness
determination, since the same elements that animate the anticipation
determination regarding genus-species situation will impact the
obviousness determination. In particular, the element of motivation
or suggestion to combine, which is necessary for an obviousness
rejection, will be significantly impacted by whether the factors above
suggest the claimed materials are closely or distantly related. For
example, in a small genus where each species can be immediately
envisaged, a species may be legally anticipated by the genus.80 As the
number of species rises, for instance, the 1200 species being
76. See id. at 383.
77. In re Bell, 991 F.2d 781, 784 (Fed. Cir. 1993).
78. MARTIN J. ADELMAN, PATENT LAW PERSPECTIVES § 2.2[4] (2d ed. 2000).
79. Id.
80. See In re Schaumann, 572 F.2d 312 (C.C.P.A. 1978).
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permitted under the facts of Merck, the species may be rendered
obvious by the genus.8 ' When the number of species reaches
stratospheric heights, as in Bell (1036 different species) or in Baird
(millions of species), the species is not obvious from the teaching of
the genus.8 2
A. Genus-Species Case law Applied to Claim 1
In applying genus-species case law to Claim 1, Panels A-E
are treated identically to the chemical analysis described above.
Applying the six-factor Adelman tests8 3 to oligonucleotides, several of
the factors are shared in common by all oligonucleotides including
those described in Figure 1. Regarding the third factor-the number
of properties shared by compounds in the genus-all oligonucleotides
share a number of structural properties; oligonucleotides are
carbohydrate polymers composed of the same four monomeric
species which are capable of hybridization to complementary
sequences. These sequences are ordinarily found in a duplex helical
form whose exact properties are determined by the precise order and
ratio of the monomeric components.8 4 The only properties not
necessarily shared by oligonucleotides are those due to differing
sequences which result in different targets for duplex formation.
Both the prior art and the claimed oligonucleotide share the
same chemical properties with regard to the fourth factor-the
relationship of the properties of the claimed compounds to the prior
art. Any differences in properties are solely related to the different
specific sequences of the oligonucleotide and the prior art
polynucleotide which would result in different target sequences for
complementary hybridization. Finally, applying the sixth factor-
whether the compounds are mixtures or products of chemical
reactions-the oligonucleotides may be the product of chemical
reactions, but they are compounds, not mixtures.
Panel F presents the case where a single nucleotide is
changed from the prior art. Applying the first factor, the prior art
embraces a single compound. The Mullis patent may be relied upon
to teach that sequence variations function for the polymerase chain
reaction [hereinafter PCR] primers and perfect matches are not
required. Therefore, as_Mullis directs, "the primer sequence need not
81. See Merck & Co. v. Biocraft Laboratories, Inc., 874 F.2d 804, 807 (Fed. Cir. 1989).
82. See e.g., In re Baird, 16 F.3d 380, 382 (Fed. Cir. 1994); In re Bell, 991 F.2d 781, 784
(Fed. Cir. 1993).
83. See PATENT LAW PERSPECTIVES, supra note 78.
84. See GEOFFREY ZUBAY, BIOCHEMISTRY 665-679 (Prentice Hall 1983).
OLIGONUCLEOTIDE PRIMERS AND PROBES
reflect the exact sequence of the template. 85 In the present example,
the Mullis patent is combined with the prior art polynucleotide of
Panel F to create a genus of single base pair mismatches.
While the figure is illustrative, prior art nucleic acid
sequences can range from the relatively short 67 nucleotide sequence
shown in Figure 1, to thousands or even millions of nucleotides,
depending upon the prior art reference. 6 To determine the number of
possible probe sequences, the length of probes must be multiplied by
3 to yield the number of probes with single mismatches. Since there
are four nucleotides, A, C, G, and T and since every position has one
of these four bases already, at each position there are three different
possible mismatches. For example, if an A is in position 1, it can be
changed only to a C, a G, or a T to form a mismatch. To calculate the
total number of possible single mismatches in a oligonucleotide of a
given length, the calculation involves multiplying the number of
possible positional mismatches at positions 1 to the end of the
oligonucleotide, by the number of possible different probes at each
position, which will ordinarily be three since there are only three
alternate nucleotide bases. This calculation determines the number of
possible probes. Assuming the prior art sequence shown in Figure 1,
if factor 1 is applied to 67 nucleotides, with 66 of the nucleotides held
constant and only one nucleotide permitted to change at a time, there
are 3 times 67 members of the genus (or 201) single point mutations
in the prior art sequence.
A normal probe range includes lengths of 15 to 25
nucleotides, and is also the preferred range for many genetic
applications and PCRs.87 For 18 mer (partial) probes, there are 49
possible probes of the 67 nucleotide prior art polynucleotide
sequence. 88 For the full probe range of 15 to 25, adding the number
of possible probes for every member of the range of probe lengths
from 15 to 25, there are 465 possible probes. Multiplying 465 by 3 to
determine the total number of probes with single mismatches yields
the total number of single mismatch probes: 1395, including
mismatched probes.
Factor 2 leads to the conclusion that some of the members of
the group of 1395 possible mismatched probes have substantial
85. U.S. Patent No. 4,683,202 (issued July 28, 1997).
86. See e.g. Elizabeth Pennisi, Microbial Genomes Come Tumbling In, 277 Sc1. 1433
(1997).
87. See U.S. Patent No. 4,683,202 (issued July 28, 1997).
88. This result is reached by subtracting the probe length, here 18 nucleotides, from the
target sequence length, here 67 nucleotides, to result in a determination that there are 49
different contiguous 18 mer probes which are fully complementary to the 67 nucleotide prior art
oligonucleotide.
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structural similarity in a purely chemical sense, but information-wise
are very different. For example, while two probes which overlap
except for one nucleotide or which differ by a mismatch are
structurally nearly identical, two non-overlapping probes may have
completely unrelated sequences, but identical chemical compositions.
Factor 5 indicates that the two parameters concerning the
particular sequence and particular length of a group of prior art
compounds are variable. Considering these factors as a whole in view
of Merck, one could argue that a single point mutation in a short 67
nucleotide prior art sequence would be prima facie obvious since it
represents selection of 1 compound out of 1395 compounds, all of
which would have identical hybridization properties. 89 However, as
the length of the sequence increases beyond 67 nucleotides and the
number of mismatches increases beyond a single mismatch, the
number of compounds in the genus will rapidly rise to numbers closer
to those in the Baird decision rather than the small genus found in
Merck.90 Thus, longer sequences with more mismatches are likely to
be nonobvious, based upon the application of the Adelman factors.
In Panel G, the number of species is much larger, and the fact
pattern is more like the situation in Bell. The size of the genus in
Panel G would be the four possible nucleotides held to the 1 1th power.
Further, there is no assurance that any large portion of this genus
would function to specifically detect any particular sequence.
Applying factor 2 is slightly counterintuitive, since every
larger sequence would encompass the 7 nucleotides in the prior art,
meaning that there would be some identical structure in the entire
genus of 4,194,304 oligonucleotides-four possible nucleotides held
to the I1 th power. However, the vast majority of the genus would not
function in a manner homologous to the claimed oligonucleotide.
Factor 5 relates the two variable parameters of sequence and
length. Considered in their entirety, these factors appear to place
analysis of obviousness for Panel G closer to Bell than to Merck
particularly given the absence of a reasonable expectation that each
member of the genus would be functionally homologous. 91
Therefore, the analysis in Bell would render the oligonucleotide in
Panel G nonobvious.
89. See Merck & Co. v. Biocraft Laboratories, Inc., 874 F.2d 804, 807 (Fed. Cir. 1989).
90. Id. at 807; see also In re Baird, 16 F.3d 380, 382 (Fed. Cir. 1994).
91. See In re Bell, 991 F.2d 781, 784 (Fed. Cir. 1993); See Merck & Co., 874 F.2d at 807.
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B. Genus-Species Case Law Applied to Claim 2
In Claim 2 the oligonucleotide is claimed using the closed language
phrase, "consisting of." As above, the anticipation and nonobvious
determinations made regarding Panels A and B remain the same. The
analysis of Panel G is nearly identical to the analysis above for Claim
1, since the concern in Panel G is the absence of implicit teaching of
the 11 missing nucleotides. The use of "comprising" within the claim
does not enter the analysis. Panels F, C, D, and E, respectively, show
decreasing sizes of the possible structural genus. There is also
abundant prior art that suggests how to make primers and probes from
larger sequences, as well as equally abundant prior art that teaches the
means necessary to make such prior art.
One last element, relevant because of the CAFC's holding in
Merck-the genus is obvious when each member would be expected
to function-is evidence that each oligonucleotide would be expected
to function.9 2 There is prior art that has tested every possible
complementary oligonucleotide, including lengths ranging from
monomers, 93 to 17 nucleotides, to a 122 nucleotide sequence, for the
ability to hybridize, and found that DNA hybridized to most of the
array.94 This prior art supports the kind of "equivalence" that the
CAFC relied upon in Merck.
Another area with abundant prior art is sequencing by
hybridization, where every oligonucleotide of a certain size is
synthesized on a micro array and hybridized to the target sequence. 95
Such arrays have been made and tested with oligonucleotides that
have each of the 65,536 different oligonucleotides in 8-nucleotide
lengths.9 6 Based upon the hybridization pattern, the sequence of the
target can be determined by a methodology that relies upon the
functional equivalence of hybridization of every oligonucleotide on
the array.9 7
The analysis and conclusions are the same under Adelman
factors 3, 4, and 6 for Panels C-F with Claim 2 as they were for
Panels C-F with Claim 1. With Claim 2, factor 5 though, differs
between Panels C-F. In Panel F, the parameters that vary are the
length of the oligonucleotide and the sequence of the oligonucleotide.
92. See Merck & Co. 874 F.2d at 807.
93. A monomer is a single unit which can be combined with other monomers to form a
polymer, for example, a nucleotide is a monomer which, when combined with other nucleotides,
forms an oligonucleotide. See BIOCHEMISTRY supra note 84, at 667.
94. Milner, supra note 59. 59
95. See U.S. Patent No. 5,525,464 (issued June 11, 1996).
96. Id.
97. Id.
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Whereas, Panel C has the same two parameters, but because no
sequence mismatches are permitted, there is less variability found
within the sequence of the oligonucleotide. Panels D and E both have
changes in the sequence of the oligonucleotide; however, since both
also have prior art oligonucleotides of 18 nucleotides in length, that
parameter is expressly taught by the prior art references. Panel E also
has a reduction in the variability in the sequence parameter since the
prior art oligonucleotide suggests a particular region of the prior art
polynucleotide.
Factor 2 analyzes structural similarity, and in this instance
there is abundant chemical structural similarity. However, the
information content imposed by the specific arrangement of the
nucleotides indicates that, except for Panel E, there is no structurally
similar oligonucleotide. Panel E has an oligonucleotide which
overlaps 14 nucleotides out of 18 total nucleotides, yielding close to
78% homology.98
Finally, factor 1 shows a decreasing genus size from Panel F
to Panels C through E, respectively. In parentheses next to the
number calculated for the prior art in Figure 1 is a number based on a
prior art sequence of 5000 nucleotides in length. The number in
parentheses shows the calculated genus size, not just for the
hypothetical small sequence, but also a size that is more relevant to
the typical real-life situation that would exist in the prior art, where
the prior art sequences would be larger than the sequence in Figure 1.
The number in parentheses represents a calculation for the more
common prior art situation, where the sequence is 5000 nucleotides in
length. Panel F has 1395 (164,340) oligonucleotide species which fall
within its genus claim, given a prior art teaching of oligonucleotide
lengths between 15 and 25 nucleotides, as taught by Mullis.99 Panel C
has a genus size of 465 (54,780) oligonucleotide probes, given a prior
art sequence 67 nucleotides in length and permitting the
oligonucleotide length to vary between 15 and 25 nucleotides. Panel
D has a prior art oligonucleotide which teaches a length of 18
nucleotides. Therefore, the number of 18 nucleotide length
oligonucleotides in a 67 nucleotide sequence would be 49 (4,982).
While Panel D also teaches a preferred location, this teaching does
not teach a method estranged from locating the oligonucleotide at
other positions, but simply teaches a single preferred embodiment of a
98. See D. Wen et al., Erythropoietin Structure-Function Relationships: High Degree of
Sequence Homology Among Mammals, 82 BLOOD 1507.
99. See U.S. Patent No. 4,683,202 (issued July 28, 1997).
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method to arrive at an 8-nucleotide sequence.1°° Panel E has an
overlapping prior art oligonucleotide which also teaches the 18
nucleotide length, so if the claimed oligonucleotide is directed to that
length and an overlapping region, only 35 (35) species are present in
the genus of oligonucleotides suggested by the prior art.
Evaluating the Adelman factors with regard to the precise
factual pattern given in the panels, the situations posed in Figure 1
appear to be closer to the court's determination of obviousness in
Merck than to the decisions in Baird or Bell, which found the
sequences nonobvious. In each of these cases the number of species
is relatively low and the prior art would expect every member of the
species to function in a predictable and identical manner, just like the
diuretic compositions in Merck.10 1 Because the prior art teaches an
equivalence among 65,536 different oligonucleotides, even the higher
numbers of species shown in parentheses for a genus of
oligonucleotides which hybridize to a 5000-nucleotide prior art
sequence might be found prima facie obvious. The fact patterns of
Panels D and E, with 4982 and 35 different species members
respectively, each comprise a genus that is sufficiently small,
sufficiently homogenous, and whose expected function is likely to fall
within the scope of Merck; particularly since each of the other
Adelman factors would support a finding of prima facie obviousness.
Panel C is still a relatively small genus, compared to the millions of
different sequences in Baird or the immense exponential numbers in
Bell. Panel F begins to approach a genus size more comparable to
that in Baird and further faces the issue that the precise sequence is
not taught in such a way that several of the other Adelman factors
oppose an obviousness determination. Thus, based upon this analysis
using the Adelman factors, Panels D and E would be strongly
expected to yield a result of obviousness, Panel C would likely result
in a determination of obviousness, and Panel F would likely be found
nonobvious.
VII.BIOTECHNOLOGY CASE LAW
The CAFC has approached the issue of the obviousness of DNA with
an amalgamation of chemical case law and genus-species case law,
with several novel twists. The decisions have been somewhat
controversial. 10 2 The CAFC also has two lines of case law dealing
with obviousness and written description of DNA sequences. The
100. See MANUAL OF PATENT EXAMINING PROCEDURE § 2123 (7"' ed. 2000).
101. See Merck & Co. v. Biocraft Laboratories, Inc., 874 F.2d 807 (Fed.Cir. 1989).
102. See Jeffrey Dillen, Comment, DNA Patentability-Anything but Obvious, 1997 WIS. L.
REV. 1023, 1045 (1997).
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first line of case law deals with the obviousness of large DNA
sequences, given less than complete information regarding the
nucleotide sequence, and the second lineage deals with what
constitutes a written description of a DNA sequence to support claims
under the first paragraph of 35 U.S.C. § 112.
The first lineage begins with Amgen, where the CAFC
determined that a gene is not conceived until its sequence is known
and defined.10 3 The next case is Bell, where the USPTO rejected a
claim drawn to nucleic acids which encoded the human insulin
growth factor protein as obvious in light of two references. 0 4 The
first reference taught the amino acid sequence of the protein and the
second taught a method of isolation of nucleic acids using probes
designed with the protein's amino acid sequence. 10 5 The CAFC
argued that there would be 1036 possible sequences for the nucleic
acid sequence and that this very large genus rendered the claim
nonobvious. 1
0 6
In Deuel, the CAFC focused on the extremely large genus
sizes of isolated cDNA sequences, 107 where the prior art has no
specific defined sequence. That decision indicates that reliance upon
methods which are generically capable of isolating the genes, without
more, is insufficient.10 8 The CAFC further stated, "[w]hat cannot be
contemplated or conceived cannot be obvious."' 0 9 While the court
did not elucidate this statement, routine knowledge of the issues
involved in cloning genes using partial protein sequences can identify
some of the problems with which the CAFC was concerned. Using a
partial protein sequence and the appropriate cDNA library, screening
could identify the full-length gene of interest, or screening could
identify alternate splice variants, alternate genes, or artifacts."1 °
Finally, in performing the screening, the sequence of the entire gene
cannot be known. It is only this specific, defined nucleotide sequence
however, that will likely be referred to as not "contemplated" or
"conceived."
103. See Amgen, Inc. v. Chugai Pharmaceutical Co., 927 F.2d 1200, 1206 (Fed. Cir.
1991).
104. See In re Bell, 991 F.2d 781, 782 (Fed. Cir. 1993).
105. See id. at 783.
106. See id. at 784-85.
107. cDNA is a DNA copy of an mRNA generated by a reverse transcriptase. See GENES
V, supra note 5, at 1237.
108. See In re Dcuel, 51 F.3d 1552, 1559 (Fed. Cir. 1995).
109. Jd. at 1558.
110. See e.g. M. Mladinic et al, 'Specific' Oligonucleotides Often Recognize More Than
One Gene: The Limits of in Situ Hybridization Applied to Gaba Receptors, 98 J.NEUROSCIENCE
METHODS 33 (2000).
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The second lineage of cases, which involve the written
description requirement, is logically consistent with Deuel. Written
description cases are relevant to the determination of the prima facie
obviousness of primers over larger nucleic acid sequences, since that
which is not described cannot be obvious.11' Beginning with Fiers v.
Revel, the CAFC imposed the requirement that the written description
of a nucleic acid requires the sequence of the nucleic acid.' 12 As the
CAFC stated "[a]n adequate written description of a DNA requires
more than a mere statement that it is part of the invention and
reference to a potential method for isolating it; what is required is a
description of the DNA itself.""' 3 The CAFC reaffirmed this position
in Regents of Univ. of California v. Eli Lilly, stating "a fortiori, a
description that does not render a claimed invention obvious does not
sufficiently describe that invention for purposes of § 112, 1.": 4 The
CAFC recently noted in Enzo Biochem v. Gen-Probe that the subject
matter of the claims "is similarly defined only by the function of the
claimed probes," which does not identify the chemical structure of the
probes themselves. 1 5 These cases are consistent with Deuel since,
whether a particular nucleic acid sequence is found to be obvious or
described, the CAFC has required that the particular nucleic acid
sequence be known. In these situations, the CAFC finds it
insufficient to argue that one could get the sequence through mere
routine practices. However, no court has addressed the situation at
issue in this Comment: where an entire particular sequence is known,
and the alleged invention lies in the selection of a small, defined
segment of that particular defined and known sequence.
A. Biotechnology Case law Applied to Claim 1
Panel F represents the mismatch situation where the prior art does not
teach one of the nucleotides of the claimed oligonucleotide. This lack
of teaching constitutes a lack of written description of the particular
oligonucleotide. No possible selection of a primer which is identical
to the prior art sequence can result in the claimed oligonucleotide.
There are generic methods to screen and sequence a number of allelic
variants of the prior art sequence," 16 one of which might turn out to
111. SeelnreDeuel, 51 F.3d 1552, 1559 (Fed. Cir. 1995).
112. See Fiers v. Revel, 984 F.2d 1164, 1169-70 (Fed. Cir. 1991).
113. Id. at 1170.
114. Regents of Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1993).
115. Enzo Biochem, Inc. v. Gen-Probe Inc., 2002 U.S. App. LEXIS 5642, at *1020 (Fed.
Cir. Apr. 2, 2002).
116. Allelic variants are naturally occurring mutations in a gene which represents
differences between individuals. See GENES V supra note 5, at 1244.
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comprise the sequence of the claimed oligonucleotide."1 7 However,
the CAFC in Deuel indicates that a general method of isolating allelic
variants would not render the claimed, specific oligonucleotide
obvious.1 8 Therefore, the oligonucleotide situation in Panel F would
likely be nonobvious under the prior art.
Panel G of is similar to Panel F, but with less prior art. Panel G is
directly analogous to the situation in Deuel, where the prior art
sequence was used to screen a library which, given sufficient
experimentation, would have resulted in the claimed oligonucleotide.
However, the CAFC suggests that the inability to conceive in advance
which nucleotides will be attached to the prior art sequence producing
the claimed oligonucleotide renders the claimed oligonucleotide
nonobvious.119 This is consistent with the written description
decisions, since there is no written description of the oligonucleotide
in the prior art and an oligonucleotide which has not been described
cannot be obvious. Therefore, the oligonucleotide in Panel G is also
nonobvious over the prior art.
B. Biotechnology Case Law Applied to Claim 2
The anticipation and nonobvious determinations made
regarding Panels A and B remain the same as in the chemical and
genus-species analysis of Claim 2. Further, the analysis of Panels F
and G is identical to that given for Claim 1. As before, Panels C-E
represent situations in which the prior art gives increasing motivation
to the selection of the specific oligonucleotide. Unlike the case in
Lilly, the prior art sequence from which the oligonucleotide is derived
is completely known and described. That is, the complete sequence
of the oligonucleotide is found in the prior art and a claim to every
18-nucleotide primer from the prior art sequence would be properly
described and encompass the claimed oligonucleotide.
In Deuel, the CAFC had three separate concerns regarding the
obviousness of the DNA sequences.12 The first concern was a huge
genus size. 12 As discussed in the genus-species analysis, the genus
size in probe selection is significantly smaller than that for back-
translation of proteins into genes. Instead of a genus comprising 1036
species, the number of species even in a large 5000 nucleotide
117. See L. Larsen et al., High Throughput Mutation Screening by Automated Capillary
Electrophoresis, 3 COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING 393 (2000).
118. SeelnreDeuel, 51 F.3d 1552, 1554 (Fed. Cir. 1995).
119. Seeid. at 1558.
120. See id. at 1555.
121. See id. at 1559.
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sequence genus will be less than 55,000, as calculated by the method
discussed in the genus-species analysis. The largest genus for a
particular example, such as Panel C, would comprise 465 members.
The genus size would be smaller in Panels D and E, since there is less
variability between the prior art and the hypothetically claimed
oligonucleotide in those panels; the sequences are closer in length and
position. Panel E, which teaches a particular probe size and suggests
a particular preferred oligonucleotide location which overlaps the
location of the hypothetical probe, permits very little variability which
significantly reduces the genus size. Thus, the situation with regard
to genus size in Claim 2 in the prior art situations of Panels C-E is
unlike the genus size in Deuel. The genus sizes in these panels are
many factors smaller than those at issue in Deuel.
The second concern in Deuel was that the prior art lacked the
specific, defined sequence which was the subject of the claim. 122 In
the current case, however, the prior art in Panel C comprises the
specific, defined sequence. The prior art in Panels D and E not only
comprise the specific, defined sequence, but further suggests
particular sized oligonucleotides and particular locations that are
especially of interest. This suggestion results from the fact than an
ordinary practitioner is likely to first review the prior art for desirable
locations for oligonucleotides and use such prior art locations as the
starting point for oligonucleotide design.
The only case in which preexisting sequence was present was
Mayne, where substitution of a known cleavage site with a particular
amino acid sequence into a fusion protein was deemed obvious. In
the present fact pattern, the expected functional equivalence of every
member species of the genus of probes suggests the homologous
oligonucleotides will be functional. 123 This suggestion, combined
with the ability of a computer or scientist to completely define each
and every species member solely through the prior art, supports prima
facie obviousness of the oligonucleotides. There is greater suggestion
of obviousness in Panels D and E, where there is an express
homologue present on the same prior art sequence to suggest alternate
compounds. These presumptions of obviousness would be rebuttable,
however, under the logic of In re Papesch. 1
24
The third issue presented by Deuel is that of whether a
compound can be defined by the process of identification. The CAFC
has stated that "[t]he fact that one can conceive a general process in
advance for preparing an undefined compound does not mean that a
122. Id.
123. See In re Deuel, 51 F.3d 1552, 1558 (Fed. Cir. 1995).
124. See In re Papesch, 315 F.2d 381,391 (C.C.P.A. 1963).
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claimed specific compound was precisely envisioned and therefore
obvious., 121 While the fact patterns of Panels C-E have a claimed
oligonucleotide, which may be deemed an undefined compound in
some sense, the lack of definition is of an entirely different type and
magnitude than that referred to and intended by the court in Deuel. In
Deuel, no nucleic acid sequence was known in the prior art. The
entire process and method cited for the rejection were devoted to
isolating and sequencing unknown nucleic acids in order to identify
the particular nucleic acid sequence of interest.1 26 This is in direct
contrast to the current fact pattern, where the entire nucleic acid
sequence is known in the prior art, and Panels D and E, where
oligonucleotide homologues, drawn to the particular prior art
sequence and target sequence, are known in the prior art. Further
distinguishing the oligonucleotide primer and probe situation from the
situation in Deuel is the nearly 100% expectation of success in probe
identification. 127 There is also prior art which shows that essentially
every probe is expected to hybridize to its complementary DNA
target. '28
Therefore, analysis of the fact patterns in Panels C-G, using
the biotechnology case law, supports the position that where the prior
art does not teach the sequence of the oligonucleotide-as in Panels F
and G-the oligonucleotide is nonobvious. Where the prior art
teaches the nucleotide sequence from which the oligonucleotide is
derived-combined with the substantial skill in the prior art in
selecting oligonucleotides and the prior art demonstrating the
functional equivalence and expectation of success of every
oligonucleotide in hybridization reactions-it can be reasonably
concluded that the oligonucleotides are prima facie obvious.
VIII.CONCLUSION
Courts should analyze nucleic acid claims using a
combination of the three analytical approaches presented. The ideal
analysis would analyze the issue of equivalence, the central element
found in chemical cases, by applying the genus-species cutoffs. That
is, equivalence would depend on the size of the genus, the
relationship of the species to the genus, and the fundamental nature of
the species. Finally, the court would recognize that in biotechnology,
125. In re Deuel, 51 F.3d at 1559.
126. See id. at 1556.
127. See U.S. Patent No. 5,525,464 (issued June 11, 1996).
128. See Milner, supra note 59.
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the fundamental nature of the species termed oligonucleotides is as
carriers of biological information.
Applying these principles to oligonucleotides, courts should
find specific oligonucleotide probes and primers prima facie obvious,
when the prior art provides the complete sequence from which these
probes are drawn. That is, when the invention is solely based upon
routine selection of a small DNA piece from a larger prior art
sequence of DNA, the invention should be deemed prima facie
obvious in the absence of any secondary considerations. Whether
applying the chemical case law such as Mayne, the genus-species
case law of Merck, or the biotechnology case law in Deuel, each
supports the obviousness of primers and probes where the prior art
teaches the entire sequence. When the prior art does not teach the
sequence, this same set of case law support a finding of
nonobviousness.

